Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“Results from Osimertinib + Necitumumab module of phase II ORCHARD study published in JCO.

Patients with EGFR-Mutated NSCLC with progression on osi and EGFR amplification or secondary EGFR mt received Osimertinib 80mg + Necitumumab D1/8 q21d. RR 11%, PFS 4m, OS 11.4m, 53% had G3+ AE.”

Title: ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Journal: JCO

Authors: Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Lau, Helena A. Yu

Read the full article.

ORCHARD

Stephen V Liu Shared ORCHARD Study Results on Osimertinib Plus Necitumumab in EGFR-Mutated NSCLC Published in JCO

“Results from Osimertinib + Necitumumab module of phase II ORCHARD study published in JCO.

Patients with EGFR-Mutated NSCLC with progression on osi and EGFR amplification or secondary EGFR mt received Osimertinib 80mg + Necitumumab D1/8 q21d. RR 11%, PFS 4m, OS 11.4m, 53% had G3+ AE.”